6:04 AM ET
8-K/A
M&A Deal
Ensysce Biosciences M&A Deal with Cy Biopharma, Inc.
Ensysce Biosciences completed the acquisition of Cy Biopharma, Inc. on August 5, 2026, through a two-step merger process. As consideration, Ensysce issued 282,122 shares of Series C Preferred Stock to Cy Biopharma equityholders, with each share convertible into 1,000 shares of common stock. This filing (Amendment No. 2) provides required historical and pro forma financial statements related to the transaction.
- Counterparty
- Cy Biopharma, Inc.